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Abstract: Attention-deficit hyperactivity disorder is a frequent condition in children and often 
extends into adulthood. Use of immediate-release methylphenidate (MPH) has raised concerns 
about potential cardiovascular adverse effects within a few hours after administration. This study 
was carried out to investigate acute effects of MPH on electrocardiogram (ECG) in a pediatric 
population. A total of 54 consecutive patients with attention-deficit hyperactivity disorder 
(51 males and 3 females; mean age =12.14±2.6 years, range 6–19 years), receiving a new prescription 
of MPH, underwent a standard ECG 2 hours before and after the administration of MPH 10 mg per 
os. Basal and posttreatment ECG parameters, including mean QT (QT interval when corrected 
for heart rate [QTc]), QTc dispersion (QTd) interval duration, T-peak to T-end (TpTe) intervals, 
and TpTe/QT ratio were compared. Significant modifications of both QTc and QTd values were 
not found after drug administration. QTd fluctuated slightly from 25.7±9.3 milliseconds to 
25.1±8.4 milliseconds; QTc varied from 407.6±12.4 milliseconds to 409.8±12.7 milliseconds. 
A significant variation in blood pressure (systolic blood pressure 105.4±10.3 vs 109.6±11.5; 
P0.05; diastolic blood pressure 59.2±7.1 vs 63.1±7.9; P0.05) was observed, but all the 
data were within normal range. Heart rate moved from 80.5±15.5 bpm to 87.7±18.8 bpm. 
No change in TpTe values was found, but a statistically significant increase in TpTe/QTc intervals 
was found with respect to basal values (0.207±0.02 milliseconds vs 0.214±0.02 milliseconds; 
P0.01). The findings of this study show no significant changes in ECG parameters. TpTe 
values can be an additional parameter to evaluate borderline cases.
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Introduction
Attention-deficit hyperactivity disorder (ADHD) is a common behavioral disorder 
characterized by symptoms of inattention, impulsivity, and hyperactivity that impact 
several domains of the life of patients, their family, and society.1,2 Patients with 
untreated ADHD are associated with poorer long-term self-esteem and social func-
tioning outcomes than no-ADHD controls.3,4
Treatments and interventions for ADHD are different and include psychological 
therapies and pharmacological treatment, especially for severe clinical cases. Stimu-
lants, such as amphetamines and methylphenidate (MPH), represent the mainstay of 
pharmacological treatment for ADHD.5 Amphetamines act by increasing presynaptic 
release of dopamine and other biogenic amines in the brain while MPH, a substituted 
phenethylamine, inhibits the reuptake of dopamine and norepinephrine and therefore 
its pharmacology is identical to that of amphetamines.6
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There is strong evidence that MPH is effective in treating 
ADHD, but recently, concerns have increasingly been raised 
about the adverse effects of this drug. In the last few years, 
several studies about the cardiovascular safety of stimulant 
medications were carried out.7–12 Stimulants and MPH 
increase blood pressure (BP) and heart rate (HR) in patients 
with ADHD,13–17 although these cardiovascular effects do not 
seem to be severe.18–20 Nevertheless, most evidence is based 
on clinical reports from small populations, so it remains con-
troversial whether the use of stimulants is potentially associ-
ated with serious adverse cardiovascular events or otherwise. 
A recent nationwide prospective cohort study suggests that 
cardiovascular events are rare in children and adolescents 
but twice as likely in stimulant users as in nonusers with a 
complex, time- and dose-dependent relationship between 
cardiovascular adverse events and stimulant treatment.21
Stimulant drugs can be proarrhythmogenic because 
they are closely related to sympathomimetic amines. The 
autonomic nervous system plays an important role in sud-
den cardiac death (SCD). However, it is hard to establish a 
strict connection between drugs and sudden cardiac arrest 
in children and adolescents because SCD is a very rare 
event in pediatric populations. It is likely that significant 
changes of HR variability reflect diminished vagal tone and 
represent one of the key factors leading to SCD in adults.7 
A pilot study by Buchhorn et al reports an improvement of 
HR variability in children under stimulant medication.16 The 
authors assume that this effect may be an important predictor 
of cardiovascular risk.
Drug-induced SCD is most commonly caused by torsades 
de pointes, a potentially life-threatening, polymorphic, 
ventricular tachycardia often associated with a QT interval 
prolongation. In clinical practice, several drugs are able to 
induce QT/QT interval when corrected for HR (QTc), pro-
longation and torsades de pointes.22 QT interval monitoring 
(QTc) is widely used as a predictor of fatal arrhythmias.23 
The QTc dispersion (QTd), a measure of the interlead varia-
tion in the QT, is believed to be a more reliable predictor for 
cardiovascular mortality in the general population. A QTc 
interval greater than 500 milliseconds, or a QTd greater 
than 100 milliseconds, is considered a risk factor for fatal 
arrhythmias.24 More recent studies indicate that prolonga-
tion of the interval between the peak and the end of the 
T wave (T-peak to T-end [TpTe]) on the 12-lead electrocar-
diogram (ECG) can represent a new marker of ventricular 
arrhythmogenesis. In fact, prolongation of the TpTe interval, 
measured in lead V5, is considered independently associated 
with SCD, and it can be a suitable risk indicator even when 
the QTc is within range or not measurable due to prolonged 
QRS duration.25,26
To date, the studies investigating the cardiovascular 
risk of immediate-release methylphenidate (IR-MPH) have 
exclusively considered the QTc and QTd variations.27 TpTe 
and TpTe/QT intervals, along with QTc and QTd modifica-
tions have not been investigated in the context of ADHD 
and drug-related cardiovascular adverse effects. We there-
fore performed an observational prospective study aimed at 
examining the modifying effect of IR-MPH on the cardio-
vascular system in pediatric patients diagnosed with ADHD, 
in particular by measuring the acute effects of IR-MPH on 
the ventricular repolarization through TpTe and TpTe/QT 
intervals, along with QTc and QTd.
Experimental procedures
study population
Children and adolescent patients (mean age =12.14±2.6 years, 
range 6–19 years) were enrolled into this observational, 
prospective study to assess the arrhythmic risk of IR-MPH. 
Patients were considered eligible for the study if they were 
drug-naïve ADHD outpatients, had ADHD diagnosed accord-
ing to Diagnostic and Statistical Manual of Mental Disorders, 
Fifth Edition (DSM-5) criteria,28 were attending the Unit of 
Child Neurology and Psychiatry of the University Policlinic 
of Messina between September 2013 and March 2014, and 
were new users of IR-MPH. None of the included patients 
had a history and signs or symptoms of cardiovascular, 
pulmonary, or endocrine disorders. The study was approved 
by the local ethics committee. Subjects and parents received 
detailed information about characteristics, potential adverse 
effects, and different treatment options for ADHD. All par-
ents gave their written informed consent, and all the patients, 
when able, gave their consent as well.
study design
In all enrolled patients, IR-MPH was started at an initial dos-
age of 5 mg/day and progressively titrated over 4 weeks until 
the therapeutic dose was achieved. The low and medium doses 
were 10 mg and 30 mg, respectively, for each child according 
to his/her weight. The high dose was 60 mg reached by only 
three adolescents. All patients in the study had body weight 
higher than 17 kg, and therefore, the range of dose adminis-
tered was between 0.68 mg/kg body weight and 0.87 mg/kg 
body weight. Each treatment condition was administered 
7 days, twice or three times daily, at breakfast (approximately 
7.30 am), at lunch (approximately 12.30 pm), and in some 
cases, early afternoon (approximately 3.30 pm).
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For each patient, two standard 12-lead ECGs were 
obtained at a paper speed of 25 mm/second with the same 
instrument (Cardioline delta 3 plus), on the same day and 
under similar conditions. The first (predose) ECG examination 
was performed before the administration of the first daily 
dose of IR-MPH; the second (postdose) ECG was executed 
2 hours after drug intake, simultaneously with the serum peak 
of MPH.29 Predose ECG was executed at least 16 hours after 
the administration of the last MPH dose on the previous day; 
therefore, MPH serum concentrations were minimal at the 
time of the examination. The duration of QT intervals was 
measured manually, by an experienced cardiologist, in all 
leads in which the onset of the QRS complex and the return 
of T wave to baseline were clearly identified. The QT dura-
tion was corrected for HR according to the Bazett’s formula 
to produce QTc and averaged for all assessed leads (mean 
QTc). If respiratory sinus arrhythmia was present, the QT 
interval was measured in all leads where RR intervals were 
almost equal. TpTe interval was measured from the peak of 
the T wave to the end of T wave in lead V5.26 The TpTe/QT 
ratio was calculated as the ratio of TpTe in that lead to the cor-
responding QT interval.25,30,31 HR, RR, PR, and QRS intervals 
were also measured. QTd was calculated as the difference 
between the longest and shortest individual lead QTc. QTc 
intervals 450 milliseconds or 60 milliseconds longer than 
at baseline and QTd 100 milliseconds were considered 
abnormal.32,33 Normal values for TpTe interval and for TpTe/QT 
ratio, calculated on V5 leads, were ranged from 4 milliseconds 
to 100 milliseconds (mean 63.3±11.38 milliseconds, median 
60 milliseconds) and from 0.12 to 0.29 (mean 0.195±0.0344, 
median 0.188), respectively.25 Basal and 2-hour postintake 
ECG parameters, including QTc, QTd, and TpTe ratio interval 
duration, were compared.
statistical analysis
The baseline and 2-hour postintake ECG parameters 
were presented as mean ± standard deviation. Ranges 
were also presented for the respective measurements. 
The baseline/posttreatment measures were compared using 
the paired-samples, two-sided t-test. Statistical significance 
was accepted at a P0.05 level. Data analyses were per-
formed using SPSS® for Windows® package.
Results
A total of 54 subjects completed the study (51 males and 
3 females, mean age 12.14±2.6 years, range 6–19 years). 
Therapeutic dosages were obtained within a month after the 
beginning of MPH treatment, in all enrolled patients. The 
average final dose of IR-MPH was 18.5 mg/day, administered 
in two to three divided doses (range 10–60 mg/day) according 
to clinical individual needs.
electrocardiographic changes
The mean, standard deviation, ranges, t, P, and d values of the 
ECG measurements before and 2 hours postintake of IR-MPH 
are shown in Table 1. No abnormal findings were observed 
in the ECG results at both times, including any changes in 
voltages, axes, or morphology. Moreover, there was no sig-
nificant difference noted in QTc and QTd intervals between 
baseline and 2-hour postintake determination. No patient 
exhibited a QTc interval greater than 500 milliseconds or a 
QTd greater than 100 milliseconds, at both determinations. 
However, in all patients, a significant variation in BP (systolic 
BP 105.4±10.3 vs 109.6±11.5; P0.05; diastolic BP 59.2±7.1 
vs 63.1±7.8; P0.05), as well as in HR values (80.5±15.5 
bpm vs 87.7±18.4 bpm), was observed between baseline and 
2-hour postintake values. No change in TpTe values was 
found (Table 2), but a statistically significant increase in TpTe/
QTc ratio was found with respect to basal values (0.207±0.02 
milli seconds vs 0.214±0.02 milliseconds; P0.01).
Discussion
Our data suggest a relative cardiovascular safety of IR-MPH 
used to treat ADHD. In our patients, the administration 
Table 1 comparison of pre-MPh and 2-hour post-MPh electrocardiogram measurements
Pre-MPH 2-hour post-MPH t (df) P Cohen’s D
heart rate (bpm) 80.5±15.5 (55–135) 87.7±18.4 (55–165) -5.139 (53) 0.01 -0.43
systolic BP (mmhg) 105.4±10.3 (85–131) 109.6±11.5 (90–135) -2.563 (47) 0.05 -0.38
Diastolic BP (mmhg) 59.2±7.1 (48–78) 63.1±7.8 (48–82) -3.324 (47) 0.01 -0.53
QTc max (milliseconds) 420.5±12 (379–440) 420.8±12 (392–447) -0.155 (53) 0.877 (Ns) -0.02
QTc min (milliseconds) 394.7±13 (358–420) 395.7±13.6 (362–426) -0.601 (53) 0.55 (Ns) -0.07
QTc mean (milliseconds) 407.6±12.4 (377.5–430.6) 409.8±12.7 (376.7–436.2) -1.773 (53) 0.082 (Ns) -0.17
QTd (milliseconds) 25.7±9.3 (4–45) 25.1±8.4 (5–40) 0.37 (53) 0.713 (Ns) 0.07
Note: Data are mean ± standard deviation (range).
Abbreviations: BP, blood pressure; MPH, methylphenidate; NS, not statistically significant; QTc, QT interval when corrected for heart rate; QTd, QTc dispersion.
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of a standard dosage of IR-MPH is not associated with a 
statistically significant increase of QTc and QTd values 
compared to baseline. Nevertheless, treatment with IR-
MPH was associated with a slight increase of systolic and 
diastolic BP. However, no patient exhibited values of BP 
exceeding the normal range, suggesting that MPH resulted 
in no consistent or clinically meaningful, short-term BP 
changes. Furthermore, we did not find significant differ-
ences between the acquired TpTe interval measurements. 
Even if we reported a TpTe/QT ratio increase between 
basal and posttreatment values, this value was within the 
normal range.
Indeed, although cardiovascular safety of MPH has 
been extensively explored in adults, in the last decade, few 
studies investigated the safety of these drugs in pediatric 
patients. Even though recent studies focusing on long-term 
safety have been performed, to date, findings about the 
association between stimulant use and adverse cardiovas-
cular outcomes are conflicting.20,21,34 A systematic review 
by Westover and Halm35 found evidence that the statistical 
power of studies performed on children and adolescents is 
limited by the sample size, although the absolute risk of 
an event is low. Studies on adults found an increased risk 
for transient ischemic attack and sudden death/ventricular 
arrhythmia, which was more suggestive of a genuine safety 
issue. However, their interpretation was limited due to dif-
ferences in population, cardiovascular outcome selection/
ascertainment, and methodology.35 In a meta-analysis by 
Mick et al about the cardiovascular effects of various Central 
Nervous System (CNS) stimulants in adults with ADHD, 
based on data from 10 placebo-controlled trials conducted 
in a pooled sample of 2,665 adults, the use of stimulants, but 
not of placebo, was associated with a statistically significant 
increase in mean HR.17 These modifications are thought to 
be mediated by the sympathomimetic effects, as well as the 
central and peripheral catecholaminergic effects, of stimulant 
medications.36,37 Minor but statistically significant changes in 
systolic BP (3.3 mmHg), diastolic BP (1.5 mmHg), and HR 
(3.9 bpm) were observed over a 1-year period in a sample 
of 432 children with ADHD aged 6–13 years, participating 
in an open-label extension trial of MPH–osmotic-controlled 
release oral delivery system, 18–54 mg.38 However, findings 
from the majority of randomized, controlled, and open-label 
studies coincide in considering that changes in BP and HR 
most commonly occur during the initial titration phase.39
At typical therapeutic doses, in all age groups, several 
studies confirmed that cardiovascular changes were minor 
or of negligible clinical significance.11,35,40–43 Apart from one 
study44 with possible methodological issues,45 available epi-
demiological studies have not shown a significant association 
between ADHD drugs use and serious cardiovascular events.46 
A recent large study47 on 1,200,438 children and young adults 
between the ages of 2 years and 24 years found no evidence 
that use of current medications for ADHD was associated 
with an increased risk of severe cardiovascular events (SCD, 
acute myocardial infarction, and stroke). Nevertheless, pos-
sible underreporting and rare deaths with the initiation of 
the medication remain reasons for concern. Two other large 
studies41,48 performed on 443,198 adults and on 241,417 chil-
dren (3–17 years of age), respectively, support the findings of 
Cooper et al47 thus confirming that ADHD drug use is not asso-
ciated with increased risk of severe cardiovascular events.
Our data further confirm the safety of MPH in pediatric 
population and provide one more cardiovascular parameter 
(TpTe), possibly useful to identify borderline cases. In fact, 
preexisting conditions and other interindividual differences 
may raise the risk of harmful adverse effects, which need 
to be investigated as carefully as possible, particularly with 
regard to cardiac sequelae.19 In a recent study, Shahani et al 
screened 691 ECGs of patients with ADHD during a 2-year 
period.49 Differences in ECG parameters were compared in 
patients already on ADHD medications compared to those 
starting a new ADHD treatment, as well as in the stimulant 
vs nonstimulant drugs group. According to our data, these 
authors conclude that screening ECGs rarely resulted in 
management changes for patients taking or starting ADHD 
medications. In view of these negative studies, it is prob-
ably not useful to monitor ECG parameters during routine 
psychostimulant treatment of children and adolescents with 
ADHD, unless there are risk factors or comorbid cardio-
vascular abnormalities. When ECG parameters need to be 
monitored for information regarding the repolarization, TpTe 
Table 2 comparison of pre-MPh and 2-hour post-MPh in T-peak to T-end values
Pre-MPH 2-hour post-MPH t (df) P Cohen’s D
TpTe (milliseconds) 75.9±6.2 (56–88) 77.4±6.2 (56–88) -1.483 (53) 0.144 (Ns) -0.24
TpTe/QTc 0.207±0.02 (0.140–0.235) 0.214±0.02 (0.156–0.253) -2.732 (53) 0.01 -0.35
Note: Data are mean ± standard deviation (range).
Abbreviations: MPH, methylphenidate; NS, not statistically significant; QTc, QT interval when corrected for heart rate.
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could be useful. TpTe is the result of the global distribution 
of the repolarization process. In a recent study, it was 
significantly and independently associated with increased 
odds of SCD in subjects with coronary artery disease. Thus, 
TpTe measurement may extend the value of repolarization 
beyond the QTc, particularly in situations where QTc is either 
normal or not valid due to prolongation of QRS duration. 
Prolonged TpTe has potential for enhancement of SCD risk 
stratification and warrants evaluation in additional, larger 
populations.26 This new ECG marker can be very useful 
when patients have instead cardiological pathologies (such 
as hypertension, Brugada syndrome, or others)50 or metabolic 
diseases (like diabetes) before starting psychiatric pharma-
cological treatment. In fact, normal values of TpTe/QT ratio 
are relatively narrow, so it can be easier to find patients with 
high risks of torsades de pointes.
The most important limitation of this study includes the 
lack of a long-term follow-up. A causal link between the drug 
and the cardiovascular outcomes could not be definitively 
confirmed, as observational studies allow the investigation 
of association rather than causality. Nevertheless, given that 
ECGs were recorded 2 hours before and after the administra-
tion of MPH, it is improbable that the outcomes observed 
were not due to drug exposure. More studies are needed to 
confirm the cardiovascular safety during long-term therapy.43 
Furthermore, the study design does not permit the investi-
gation of a time- and dose-dependent relationship between 
cardiovascular adverse events and stimulant treatment in 
children and adolescents, even though this was not within 
the scope of the study.
Conclusion
This study underlines the relative cardiac safety of IR-MPH 
in childhood, even if stimulants may exert a cardiovascular 
effect on BP and HR. MPH-induced changes seem to be 
modest and comparable with changes in cardiovascular 
functioning associated with normal daily activities. Thus, 
there appears to be a wide margin of cardiovascular safety 
when MPH is taken orally in usual doses by hyperactive 
children. However, particular caution should be exercised 
by physicians in prescribing these drugs to patients with 
a genetic predisposition to arrhythmias. It might be useful 
to carry out an ECG examination in all patients starting 
MPH therapy.10 Additionally, both QTc and QTd should be 
measured in order to warrant a reliable assessment of drug-
induced QT prolongation. TpTe can be an additional useful 
parameter. In children with known cardiac disease, arrhyth-
mia, or risk factors for cardiac disease, ADHD treatment 
should be undertaken in consultation with a medical specialist 
with competence in pediatric cardiology.23,40
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